Patriot Financial Group Insurance Agency’s Takeda Pharmaceutical TAK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-1,291
Closed -$18K 1787
2022
Q2
$18K Sell
1,291
-133
-9% -$1.9K ﹤0.01% 1046
2022
Q1
$20K Buy
1,424
+1,125
+376% +$16.5K ﹤0.01% 1098
2021
Q4
$4K Sell
299
-1,408
-82% -$19.8K ﹤0.01% 1808
2021
Q3
$28K Buy
1,707
+82
+5% +$1.38K 0.01% 1080
2021
Q2
$27K Sell
1,625
-198
-11% -$3.37K ﹤0.01% 1063
2021
Q1
$33K Sell
1,823
-2,417
-57% -$43.5K 0.01% 918
2020
Q4
$77K Buy
4,240
+2,733
+181% +$48K 0.02% 567
2020
Q3
$27K Hold
1,507
0.01% 706
2020
Q2
$27K Buy
1,507
+444
+42% +$7.97K 0.01% 669
2020
Q1
$16K Buy
1,063
+611
+135% +$11.1K 0.01% 725
2019
Q4
$9K Hold
452
﹤0.01% 872
2019
Q3
$8K Buy
452
+36
+9% +$623 ﹤0.01% 853
2019
Q2
$7K Buy
416
+85
+26% +$1.55K ﹤0.01% 882
2019
Q1
$7K Buy
+331
New +$6.66K ﹤0.01% 785

Other funds holding TAK

Patriot Financial Group Insurance Agency's TAK Position: Q3 2022 in Review

Patriot Financial Group Insurance Agency sold out of Takeda Pharmaceutical (TAK) in Q3 2022, closing a stake of 1,291 shares — an estimated $18K sold.

Patriot Financial Group Insurance Agency first reported a position in TAK in Q1 2019 and held it in 14 quarters. The position peaked at $77K in Q4 2020. 277 funds tracked by Wall St. Rank hold TAK as of Q3 2022.

  • Patriot Financial Group Insurance Agency reported no remaining Takeda Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • Patriot Financial Group Insurance Agency sold 1,291 Takeda Pharmaceutical shares in Q3 2022, an estimated $18K.
  • Patriot Financial Group Insurance Agency first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 14 quarters.
  • Patriot Financial Group Insurance Agency's Takeda Pharmaceutical position peaked at $77K in Q4 2020.
  • 277 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2022.

Based on Patriot Financial Group Insurance Agency's 13F filing for Q3 2022, filed 1 Nov 2022.